Sunscreen and NSAID Photoallergy Rates Higher Than Expected

Understanding Sunscreen and NSAID Photoallergy: New Insights into Detection and Prevalence

Many people rely on sunscreens for protection and non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief, but for some, these common products can trigger an adverse reaction when exposed to light. Drug-induced photosensitivity (DIP) is a common adverse drug reaction that results in a cutaneous eruption after exposure to visible or ultraviolet (UV) radiation in patients using topical or systemic photosensitising medications, according to DermNet.

Recent research indicates that photoallergy rates for these substances may be higher than previously expected, largely as traditional testing methods may have been missing a significant number of cases. Understanding the difference between phototoxicity and photoallergy, and how these reactions are diagnosed, is critical for effective dermatological care.

What is Photoallergic Contact Dermatitis?

Photoallergy is a specific type of drug-induced photosensitivity. While phototoxic reactions are more common, a photoallergic reaction occurs when a drug or its metabolites within the skin absorb UV radiation, triggering a chemical reaction. Since the 1980s, sunscreens and NSAIDs have been the primary causes of photoallergic contact dermatitis, as noted by the Journal of Allergy and Clinical Immunology.

Common Photoallergens in Sunscreens and NSAIDs

Not all sunscreens or pain relievers cause these reactions. Certain chemical agents are more likely to act as photoallergens. A prospective multi-centre study conducted across 10 centres in seven European countries identified several prevalent photoallergens:

• NSAIDs and Other Agents: Ketoprofen was the most prevalent photoallergen identified in the study, followed by promethazine, and etofenamate.
• Sunscreens: Common culprits include butylmethoxydibenzoylmethane (similarly known as Avobenzone or Parsol 1789) and benzophenone-3 (oxybenzone). The Journal of Allergy and Clinical Immunology highlights oxybenzone as the most common photoallergen found in sunscreens.

Improving Diagnostic Accuracy: The Role of Photopatch Testing

Photopatch testing is the preferred investigation for diagnosing photoallergic contact dermatitis. However, the technique’s effectiveness can vary based on the occlusion time—the period the allergen remains on the skin before irradiation.

A study published via PubMed compared a 24-hour occlusion period against a 48-hour period. The results revealed a significant gap in detection rates:

• Sunscreen Reactions: When using a 24-hour occlusion, 53% of sunscreen photoallergic reactions were missed compared to the 48-hour occlusion.
• NSAID Reactions: A 24-hour occlusion missed 36% of NSAID reactions compared to the 48-hour occlusion.

The study found that 10% of participants reacted to sunscreen chemicals and 9% reacted to NSAIDs. This suggests that extending the occlusion time to 48 hours significantly improves the accuracy of photopatch testing in detecting these allergies.

Who is Most at Risk?

Drug-induced photosensitivity is not genetically inherited, and there is no known predilection based on age, gender, or race. However, the European study found that most participants with positive photopatch tests had a history of:

• Dermatitis on photo-exposed sites.
• Previous reactions to sunscreens or NSAIDs.
• Photosensitivity diseases.

49% of the participants in that study had a history of other dermatological conditions.

Key Takeaways

Conclusion

The discovery that a significant percentage of photoallergic reactions are missed using shorter occlusion times highlights the need for refined diagnostic protocols in dermatology. By utilizing 48-hour photopatch testing, clinicians can more accurately identify patients reacting to sunscreens and NSAIDs, allowing for safer alternative treatments and better management of drug-induced photosensitivity.